1例来那度胺致心动过缓患者的药学监护

doi:10.19803/j.1672-8629.2020.08.08

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (8): 487-490.
DOI: 10.19803/j.1672-8629.2020.08.08

1例来那度胺致心动过缓患者的药学监护

田稷馨, 苗文娟, 廖应熙, 章萍, 王晓丹, 李姗, 严海泓^*

中国医学科学院血液病医院（中国医学科学院血液学研究所）,实验血液学国家重点实验室,国家血液系统疾病临床医学研究中心,药剂科,天津300020

收稿日期:2020-07-31 修回日期:2020-07-31 出版日期:2020-08-15 发布日期:2020-07-31
通讯作者: ^*严海泓,女,副主任药师,临床药学。E-mail: yanhaihong@ihcams.ac.cn
作者简介:田稷馨,女,主管药师,博士,临床药学。

Pharmaceutical Care for a Patient with Bradycardia Induced by Lenalidomide

TIAN Jixin, MIAO Wenjuan, LIAO Yingxi, ZHANG Ping, WANG Xiaodan, LI Shan, YAN Haihong^*

Department of Pharmacy, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China

Received:2020-07-31 Revised:2020-07-31 Online:2020-08-15 Published:2020-07-31
Supported by:
重大新药创制重大专项（2017ZX09304024）

摘要/Abstract

摘要： 目的探讨来那度胺致心动过缓的药学监护,促进合理用药。方法回顾性分析临床药师参与1例滤泡性淋巴瘤患者使用来那度胺化疗后继发心动过缓的治疗过程,通过协助临床医师制定个体化治疗方案,对主要药物治疗实施药学监护。结果临床药师分析患者发生心动过缓的原因,并从患者治疗方案的选择、合并用药的调整等方面为医师提供合理化用药建议并被采纳,取得了很好的疗效。结论来那度胺心脏不良反应与其临床应用有明显的时间相关性。患者在使用来那度胺过程中如出现心律不齐症状时,临床药师及医师应结合病史、用药史仔细分析,及早诊断和治疗,从而降低患者不良反应危害、改善患者预后。

关键词: 来那度胺, 心动过缓, 药学监护, 滤泡性淋巴瘤

Abstract: Objective To explore the pharmaceutical care for a patient with bradycardia induced by lenalidomide in order to promote the rational use of the drug. Methods A retrospective analysis was conducted of the pharmaceutical care involving clinical pharmacists for a patient with follicular lymphoma, who experienced secondary bradycardia after chemotherapy with lenalidomide. Clinical pharmacists assisted physicians in developing an individualized therapeutic regimen and practiced special pharmaceutical care in the drug therapy. Results Clinical pharmacists analyzed the causes of this case of bradycardia, and gave advice to physicians about how to select therapeutic regimens and adjust concomitant medications, which was taken and achieved very good curative effect. Conclusion There is a significant correlation between the occurrence of bradycardia and the time lenalidomide is administered. If symptoms of arrhythmia occur during the use of lenalidomide, clinical pharmacists and physicians should carefully analyze the medical and medication history to initiate early diagnosis and treatment so as to reduce the harm of adverse drug reactions and lead to a better prognosis.

Key words: lenalidomide, bradycardia, pharmaceutical care, follicular lymphoma

中图分类号:

R994.11

田稷馨, 苗文娟, 廖应熙, 章萍, 王晓丹, 李姗, 严海泓. 1例来那度胺致心动过缓患者的药学监护[J]. 中国药物警戒, 2020, 17(8): 487-490.

TIAN Jixin, MIAO Wenjuan, LIAO Yingxi, ZHANG Ping, WANG Xiaodan, LI Shan, YAN Haihong. Pharmaceutical Care for a Patient with Bradycardia Induced by Lenalidomide[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 487-490.

参考文献

[1] Fowler NH, Mclaughlin P, Kwak L, et al.Lenalidomide and rituximab for untreated indolent non-Hodgkin’s lymphoma[J]. J Clin Oncol, 2009, 27(15): 8548.
[2] Wiernik PH, Lossos IS, Tuscano JM, et al.Lenalidomide mono- therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2008, 26(30): 4952-4957.
[3] 邵震,王俊淞.顺铂致430例药品不良反应报告分析[J].中国药物经济学, 2017, 12(11): 19-21.
[4] 邱爽,崔向丽,王颖. 112例吉西他滨不良反应分析[J].中国新药杂志, 20l4, 23(17): 2085-2088.
[5] 周莉莉,傅卫军,侯健.地塞米松治疗多发性骨髓瘤引起心动过缓二例病例分析[J]. 中华血液学杂志, 2010, 31(1): 48-49.
[6] 梁佳. 利妥昔单抗致心律失常1例[J].医药导报, 2016, 35(8): 900.
[7] 李晋文,章萍,廖应熙,等.利妥昔单抗注射液致过敏反应及阵发性室上性心动过速1例[J].中国药物警戒, 2019, 16(8):504-505, 507.
[8] Katodritou E, Vadikolia C, Lalagianni C, et al."Real-world" data on the efficacy and safety of lenalidomide and dexameth- asone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: A study of the Greek Myeloma Study Group[J]. Ann Hematol, 2014, 93(1):129-139.
[9] González Rodríguez AP.Management of the adverse effects of lenalidomide in multiple myeloma[J]. Adv Ther, 2011, 28(Suppl 1):1-10.
[10] Dinner S, Witteles W, Afghahi A, et al.Lenalidomide, melpha-lan and dexamethasone in a population of patients with immun-oglobulin light chain amyloidosis with high rates of advancedcardiac involvement[J]. Haematologica, 2013, 98(10): 1593-1599.
[11] 崔向丽,万子睿,侯珂露,等.增加肿瘤患者血栓风险的药物概述[J].中国药物警戒, 2017, 14(7): 430-434.
[12] 张灵,王天元,师少军,等.来那度胺致药物性心肌炎1例[J].中国医院药学杂志, 2019, 39(7): 768-770.
[13] 刘亚林,何清,王菁华,等.静注大剂量奥美拉唑导致心律失常[J].药物不良反应杂志, 2005, 7(5): 368-369.
[14] 何启燕. 继发性低钾血症致室性心律失常的心电图特点及治疗策略分析[J].重庆医学, 2018, 47(20): 2742-2746.
[15] 刘亦男摘译.无症状低血糖亦可诱发心律失常[J].中国糖尿病杂志, 2016, 24(3): 200-201.

1例来那度胺致心动过缓患者的药学监护

Pharmaceutical Care for a Patient with Bradycardia Induced by Lenalidomide

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[2]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[3]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[4]	彭苗新, 王艳琼, 许佩佩, 杨永公. 来那度胺致高级别B细胞淋巴瘤患者似癫痫样发作1例分析[J]. 中国药物警戒, 2023, 20(5): 585-587.
[5]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[6]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[7]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[8]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[9]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[10]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.
[11]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[12]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[13]	李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.
[14]	王国祥, 赵弘, 惠吴函, 苏力, 孙婉玲. 硼替佐米联合化疗致心动过缓临床分析[J]. 中国药物警戒, 2022, 19(6): 670-673.
[15]	刘蕾, 张会娟, 钱效森, 孙瑞芳. 1例磺胺脱敏方案治疗干燥综合征合并卡氏肺孢子菌肺炎的药学监护[J]. 中国药物警戒, 2022, 19(6): 680-683.